J&J is pausing recruitment for its clinical trial of a coronavirus disease 2019 vaccine; racial bias found in algorithms used nationwide in health-cost analytics software; Americans stockpile food and other essentials amid resurging pandemic fears.
Announced yesterday, Johnson & Johnson (J&J) said it is temporarily pausing recruitment and dosing for its coronavirus disease 2019 (COVID-19) vaccine candidate clinical trial after an unexplained illness in a study participant. Reported by POLITICO, the case, part of J&J’s phase 3 ENSEMBLE trial, is being reviewed by the independent drug safety monitoring board, with no further information on the patient being released. The company cautioned that adverse events, even serious ones, typically occur in any clinical study.
Reported today, a STAT investigation found that a common method of using analytics software is infusing racial bias into decision-making on who should receive stepped-up care. The study, which analyzed medical services targeted to patients who need them most, additionally found multiple algorithms across several hospitals in the United States, signaling a systemic issue as opposed to a singular event. Researchers note that the bias can produce significant differences in assessing patients’ need for special care to manage conditions like hypertension and diabetes.
Reported by USA Today, amid reports of surges in COVID-19 cases nationwide, slightly more than half of Americans said in a recent poll they have or plan to stockpile food and other essentials. Principal reasons for this include the millions who continue to work or attend school remotely, as well as fears of a resurgent pandemic. As of October 2, COVID-19 cases in the United States were at their highest in almost 2 months, and in the past week, the average grocery bill has risen 11%.
Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH
December 6th 2023ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Read More
Humana Report Shows Benefits of Value-Based Care for Patients, Physicians
December 6th 2023Patients seen at value-based care clinics received more preventive screenings and had lower risks of hospitalization and emergency room visits, according to Humana’s 10th annual value-based care report.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More